Publications (167) FRANCISCO MARTÍN MOLINA publications

filter_list

2025

  1. Donor insertion into CX3CR1 allows epigenetic modulation of a constitutive promoter on hematopoietic stem cells and its activation upon myeloid differentiation

    Nucleic Acids Research, Vol. 53, Núm. 8

  2. Exploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer

    Genes, Vol. 16, Núm. 2

  3. Tailoring CAR surface density and dynamics to improve CAR-T cell therapy

    Journal for ImmunoTherapy of Cancer, Vol. 13, Núm. 4

2024

  1. CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?

    Frontiers in Immunology, Vol. 15

  2. First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas

    Molecular Therapy Nucleic Acids, Vol. 35, Núm. 4

  3. Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome

    Frontiers in Immunology, Vol. 15

  4. NLRP3 and AIM2 inflammasomes expression is modified by LPS and titanium ions increasing the release of active IL-1β in alveolar bone-derived MSCs

    Stem Cells Translational Medicine, Vol. 13, Núm. 8, pp. 826-841

2023

  1. LRRK2 Knockout Confers Resistance in HEK-293 Cells to Rotenone-Induced Oxidative Stress, Mitochondrial Damage, and Apoptosis

    International Journal of Molecular Sciences, Vol. 24, Núm. 13

  2. Lentiviral gene therapy reverts GPIX expression and phenotype in Bernard-Soulier syndrome type C

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 75-92

  3. Lentiviral vectors for inducible, transactivator-free advanced therapy medicinal products: Application to CAR-T cells

    Molecular Therapy - Nucleic Acids, Vol. 32, pp. 322-339

  4. Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi

    Molecular Therapy Nucleic Acids, Vol. 34

  5. Reductive carboxylation epigenetically instructs T cell differentiation

    Nature, Vol. 621, Núm. 7980, pp. 849-856

  6. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

2022

  1. Editorial: Engineered immune cells in cancer immunotherapy (EICCI)

    Frontiers in Immunology

  2. Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma

    Frontiers in Immunology, Vol. 13

  3. Erratum: Physiological lentiviral vectors for the generation of improved CAR-T cells (Molecular Therapy - Oncolytics (2022) 25 (335–349), (S2372770522000687), (10.1016/j.omto.2022.05.003))

    Molecular Therapy - Oncolytics

  4. Isogenic GAA-KO Murine Muscle Cell Lines Mimicking Severe Pompe Mutations as Preclinical Models for the Screening of Potential Gene Therapy Strategies

    International Journal of Molecular Sciences, Vol. 23, Núm. 11

  5. Physiological lentiviral vectors for the generation of improved CAR-T cells

    Molecular Therapy - Oncolytics, Vol. 25, pp. 335-349

2021

  1. Anti-CD44-Conjugated Olive Oil Liquid Nanocapsules for Targeting Pancreatic Cancer Stem Cells

    Biomacromolecules, Vol. 22, Núm. 4, pp. 1374-1388

  2. Baboon Envelope Pseudotyped “Nanoblades” Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing in Human T, B, and CD34+ Cells and Knock-in of AAV6-Encoded Donor DNA in CD34+ Cells

    Frontiers in Genome Editing, Vol. 3